Myeloma overexpressed gene protein (MYEOV)

Myeloma overexpressed gene protein (MYEOV) is a gene located on chromosome 11q13.3 frequently amplified in various human cancers, most notably in multiple myeloma and several solid tumors. It is widely recognized as an oncogene due to its significant overexpression at the RNA level in malignancy and its strong association with poor clinical prognosis[1][5]. MYEOV may encode one or two human-specific protein isoforms, though evidence for functional endogenous protein is limited and controversial[2][4]. MYEOV has an established role as a competing endogenous RNA (ceRNA), modulating oncogenic pathways by acting as a molecular sponge for microRNAs, and can participate in regulatory enhancer elements influencing expression of nearby genes such as CCND1 (cyclin D1)[1][2][5]. MYEOV's precise protein function, if any, remains uncharacterized; the major oncogenic activity is attributed to its RNA transcript rather than to any confirmed protein product[5]. It is not classified as a classical therapeutic target such as a receptor or enzyme but is significant as a prognostic cancer biomarker and potential future target for RNA-based therapies[1][2][5].

Other names

Myeloma-overexpressed gene proteinOCIMOncogene in multiple myelomamyeloma-overexpressed genemyeloma-overexpressed gene proteinmyeloma overexpressed (in a subset of t(11;14) positive multiple myelomas)myeloma overexpressed gene